AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00994591
Drug: Pharmacokinetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
Trial: NCT02203955
Drug: Short-Chain Fructooligosaccharide
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 chews (8.0 g scFOS) orally for 12 months
Trial: NCT00413010
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + concurrent GAD treatment from the open-label study period
Trial: NCT04494724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT02475616
Drug: PCO371
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02475616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02663141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00019474
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01360177
Drug: Na134I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 to 150 mCi
Trial: NCT03764267
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain
Trial: NCT00958035
Drug: vehicle sterile solution (placebo)
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Trial: NCT01693432
Drug: DS (docetaxel+S-1)
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14
Trial: NCT01114100
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
Trial: NCT03764267
Drug: general anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
Trial: NCT01384058
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg per day for six weeks
Trial: NCT01384058
Drug: Ezetimibe 10/Simvastatin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
Trial: NCT04259684
Drug: gases Nitric Oxide (gNO)
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
Trial: NCT00549770
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00549770
Drug: AHU377
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00549770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648297
Drug: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/5mg, single dose fed
Trial: NCT00648297
Drug: Corzide® Tablets 80 mg/5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/5mg, single dose fed
Trial: NCT02436512
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes
Trial: NCT02137187
Drug: Optimized drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control
Trial: NCT00000252
Drug: 0% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000252
Drug: 10% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000252
Drug: 20% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000252
Drug: 30% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000252
Drug: 40% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03688555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo hard gelatin capsules
Trial: NCT02803996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
Trial: NCT03337724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Trial: NCT03077165
Drug: S42909 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Trial: NCT03077165
Drug: S42909 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Trial: NCT03077165
Drug: S42909 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Trial: NCT03077165
Drug: S42909 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
Trial: NCT03077165
Drug: S42909 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Trial: NCT01275014
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
Trial: NCT04737096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03436173
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10 mg/2.5 ml mixed with water
Trial: NCT00151892
Drug: SPD476
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day Once Daily (QD)
Trial: NCT02826772
Drug: GT0918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-tumor activity
Trial: NCT03077165
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
Trial: NCT02707640
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo, oral administration, three times daily for 24 weeks.
Trial: NCT02557984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pill
Trial: NCT02517905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration
Trial: NCT01678534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03011645
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth, single dose.
Trial: NCT02129673
Drug: VS101 Insert Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release of latanoprost into the eye
Trial: NCT02129673
Drug: VS101 Insert Dose B
RxNorm normalized name: oxytetracycline / polymyxin B Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release of latanoprost into the eye
Trial: NCT00927641
Drug: Ketoprofen Patch
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
Trial: NCT01221259
Drug: E2212
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single ascending doses ranging from 10mg to 250mg
Trial: NCT01221259
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of matching placebo
Trial: NCT01730248
Drug: INC424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablets administered orally twice daily
Trial: NCT01730248
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 50 mg hard gelatin capsules administered orally once daily
Trial: NCT00448292
Drug: Placebo for PRX-00023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Trial: NCT03033329
Drug: Single intravenous doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single doses of placebo to match MRX-4
Trial: NCT03033329
Drug: Multiple intravenous doses of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
Trial: NCT03033329
Drug: Single dose of intravenous and oral MRX-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
Trial: NCT04390152
Drug: Wharton's jelly derived Mesenchymal stem cells.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Wharton's jelly derived Mesenchymal stem cells, two doses
Trial: NCT04390152
Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
Trial: NCT04250597
Drug: GNX102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation
Trial: NCT04250597
Drug: GNX102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expansion Phase
Trial: NCT02855944
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
Trial: NCT03946163
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
Trial: NCT00745914
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT04280874
Drug: Dinoprostone 0.5 MG
RxNorm normalized name: dinoprostone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg dinoprostone applied intracervically
Trial: NCT04280874
Drug: Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg dinoprostone applied intravaginally
Trial: NCT01530243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same as tolterodine and terazosin dose
Trial: NCT02784093
Drug: Gastrograﬁn
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00684177
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Trial: NCT01446809
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03148210
Drug: Treatment strategy using evidence-based guidelines for asthma or COPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
Trial: NCT03265119
Drug: AEVI-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
Trial: NCT03265119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
Trial: NCT02099201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975143
Drug: CIP-Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
Trial: NCT02685774
Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
Trial: NCT02685774
Drug: CKD-395 0.25/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-395 0.25/500mg 2T oral administration
Trial: NCT02321865
Drug: NPC-02
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293384
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
Trial: NCT02478580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given before surgery
Trial: NCT02232256
Drug: CALPXT96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
Trial: NCT03079440
Drug: TEMCAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
Trial: NCT00140075
Drug: Epirubicin with Cyclophosphamide, followed by a Taxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Trial: NCT01231165
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/daily for 12th months
Trial: NCT01822613
Drug: LJM716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Trial: NCT01822613
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Trial: NCT03724448
Drug: aleozen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with herbal medicine
Trial: NCT03724448
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aleozen treatment
Trial: NCT01792518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00861718
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, QD
Trial: NCT00861718
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, BID
Trial: NCT00861718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral BID
Trial: NCT02247869
Drug: dose dense ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14
Trial: NCT00333229
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
Trial: NCT00333229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01907633
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
Trial: NCT00192075
Drug: 5FU/folinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
Trial: NCT00649116
Drug: Lopressor® Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT02224872
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg IV on days -6, -5, 3, 4
Trial: NCT02224872
Drug: Mycophenolic acid mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/kg PO/IV TID beginning on day 5 through day 35
Trial: NCT04608266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
Trial: NCT03527212
Drug: SJP-0035 0.001%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
Trial: NCT03527212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
Trial: NCT00003060
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003060
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00722293
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
Trial: NCT00452803
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Trial: NCT00452803
Drug: Concurrent chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Trial: NCT00687453
Drug: NPH twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of morning NPH to bedtime NPH
Trial: NCT01742429
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01742429
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT00393718
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide placebo. Injected s.c. (under the skin) once daily.
Trial: NCT03431194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no